Echinocandins in invasive candidiasis.

Autor: Simon J; University of Hong Kong, Pokfulam, Hong Kong, China., Sun HY, Leong HN, Barez MY, Huang PY, Talwar D, Wang JH, Mansor M, Wahjuprajitno B, Patel A, Wittayachanyapong S, Sany BS, Lin SF, Dimopoulos G
Jazyk: angličtina
Zdroj: Mycoses [Mycoses] 2013 Nov; Vol. 56 (6), pp. 601-9. Date of Electronic Publication: 2013 May 07.
DOI: 10.1111/myc.12085
Abstrakt: We summarise a recent meeting, sponsored by Pfizer Inc., where experts in Asia shared their clinical experience in managing IC. The echinocandins have demonstrated good activity against non-albicans infections and also azole-resistant strains, both preclinically and in recent clinical trials. As well as proving efficacious, echinocandins have a favourable safety profile and are well tolerated, including among inpatient subpopulations, such as transplant recipients and those with renal or hepatic dysfunction. In addition the echinocandins generally have minimal drug-drug interactions, unlike the oral azoles, which have multiple effects on cytochrome P450-mediated drug metabolism. Echinocandins are characterised by a good safety profile, few drug-drug interactions and good susceptibilities. With the increase in potentially azole-resistant non-albicans infections, echinocandins may become the first-line treatment of choice for many patients.
(© 2013 Blackwell Verlag GmbH.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje